Asymmetric dimethylarginine (ADMA) to monitor treatments of pulmonary hypertension

Conclusions: ADMA paralleled the hemodynamic and clinical benefit of PAH-specific treatments or BPA in patients with PAH and CTEPH. ADMA could be used as a biomarker for the monitoring of the effect of treatments in precapillary PH.

Source: European Respiratory Journal - November 20, 2019 Category: Respiratory Medicine Authors: Skoro-Sajer, N., Probst, V., Sadushi-Kolici, R., Gerges, C., Campean, I., Lang, I. Tags: Pulmonary hypertension Source Type: research